Navigation Links
Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Date:5/4/2010

RICHMOND, Calif., May 4 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic™ development programs and an overview of the company's business strategy at two investor conferences during the month of May:

  • The Ninth Annual JMP Securities Research Conference in San Francisco, at 2:00 pm PT on Monday, May 10.
  • The Bank of America Merrill Lynch Health Care Conference in New York City, at 4:20 pm ET on Wednesday, May 12.

Live webcasts of the presentations will be available on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. A replay of each presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic™ development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
2. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
3. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
4. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
5. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
6. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
7. Sangamo Announces Pricing of Public Offering of Common Stock
8. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
9. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
10. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
11. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , With the launch ... supplier in the weighing industry, to extending its expertise across the entire laboratory to ... hybridizations and more, allowing for its customers to 'Do More' in the ...
(Date:6/19/2017)... , ... June 19, 2017 , ... A colony of ... its cells and tissues by delivering pollen and nectar containing nutrients necessary for growth ... to stay healthy. , Many recent indicators point to a decline in honey bee ...
(Date:6/15/2017)... ... June 15, 2017 , ... ... secured a Series B round of financing in the amount of $6 million. ... private investors participated in the round. , The Series B funding will enable ...
(Date:6/14/2017)... , ... June 14, 2017 , ... ... 8th to discuss the initiative steered by the executive search firm, “Building Value ... of the Board of Directors of Foundation Medicine, led an open discussion with ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
Breaking Biology News(10 mins):